BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18413812)

  • 21. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
    Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
    Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
    Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
    Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic activity of the MDM2 antagonist nutlin-3.
    Secchiero P; Corallini F; Gonelli A; Dell'Eva R; Vitale M; Capitani S; Albini A; Zauli G
    Circ Res; 2007 Jan; 100(1):61-9. PubMed ID: 17138942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
    Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
    J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
    J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.
    Logan IR; McNeill HV; Cook S; Lu X; Lunec J; Robson CN
    Prostate; 2007 Jun; 67(8):900-6. PubMed ID: 17440969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
    Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
    J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
    Arya AK; El-Fert A; Devling T; Eccles RM; Aslam MA; Rubbi CP; Vlatković N; Fenwick J; Lloyd BH; Sibson DR; Jones TM; Boyd MT
    Br J Cancer; 2010 Jul; 103(2):186-95. PubMed ID: 20588277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.
    Valentine JM; Kumar S; Moumen A
    BMC Cancer; 2011 Feb; 11():79. PubMed ID: 21338495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
    Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
    J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.
    Forde JC; Maginn EN; McNamara G; Martin LM; Campiani G; Williams DC; Zisterer D; McElligott AM; Lawler M; Lynch TH; Hollywood D; Marignol L
    Cancer Biol Ther; 2011 Feb; 11(4):421-8. PubMed ID: 21131779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.